Prooxidant-antioxidant balance as a predictor of mortality: findings from the Neyshabur Longitudinal study on Ageing.

IF 1.9 4区医学 Q3 MEDICINE, RESEARCH & EXPERIMENTAL

Biomarkers in medicine Pub Date : 2025-06-18 DOI:10.1080/17520363.2025.2521253

Seyed Reza Mirhafez, Zeinab Shateri Amiri, Atena Mansouri, Saeed Mohammadian Haftcheshmeh, Peyman Habibi, Fatemeh Abdollahi, Stephen L Atkin, Tannaz Jamialahmadi, Amirhossein Sahebkar

{"title":"Prooxidant-antioxidant balance as a predictor of mortality: findings from the Neyshabur Longitudinal study on Ageing.","authors":"Seyed Reza Mirhafez, Zeinab Shateri Amiri, Atena Mansouri, Saeed Mohammadian Haftcheshmeh, Peyman Habibi, Fatemeh Abdollahi, Stephen L Atkin, Tannaz Jamialahmadi, Amirhossein Sahebkar","doi":"10.1080/17520363.2025.2521253","DOIUrl":null,"url":null,"abstract":"Background: The aim of this study was to determine PAB levels as a predictor of all-cause and cause-specific mortality in adult and elderly subjects.Methods: The data from 386 subjects who had died during the study were age- and sex-matched to 386 subjects that remained alive, and PAB levels were compared. PAB was evaluated using a mixed enzymatic/chemical method involving simultaneous oxidation and reduction of the chromogen 3,3',5,5'-tetramethylbenzidine by prooxidants and antioxidants, respectively, leading to measurable colorimetric changes.Results: PAB levels showed an increased risk of mortality (OR: 1.018; 95%CI: 1.010-1.025, p < 0.001) for each unit increase of PAB (per SD increase). When divided into quartiles, the PAB value was significantly higher for all-cause mortality in quartiles 2,3 and 4 compared with quartile 1 (PAB <34.95). Using uni & multivariate conditional logistic regression with multiple adjustments, the PAB value remained significantly different for all-cause mortality. The result of the cause-specific mortality analysis showed that the mean PAB was highest in COVID-19 infection and the respiratory diseases, and lowest in death caused by cardiovascular diseases (p < 0.05).Conclusions: Increasing PAB levels were significantly associated with increasing all-cause mortality suggesting that PAB measurement may have utility in indicating disease severity and have differential prognostic value in acute and chronic clinical scenarios.","PeriodicalId":9182,"journal":{"name":"Biomarkers in medicine","volume":" ","pages":"1-9"},"PeriodicalIF":1.9000,"publicationDate":"2025-06-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Biomarkers in medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/17520363.2025.2521253","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}

引用次数: 0

Abstract

Background: The aim of this study was to determine PAB levels as a predictor of all-cause and cause-specific mortality in adult and elderly subjects.

Methods: The data from 386 subjects who had died during the study were age- and sex-matched to 386 subjects that remained alive, and PAB levels were compared. PAB was evaluated using a mixed enzymatic/chemical method involving simultaneous oxidation and reduction of the chromogen 3,3',5,5'-tetramethylbenzidine by prooxidants and antioxidants, respectively, leading to measurable colorimetric changes.

Results: PAB levels showed an increased risk of mortality (OR: 1.018; 95%CI: 1.010-1.025, p < 0.001) for each unit increase of PAB (per SD increase). When divided into quartiles, the PAB value was significantly higher for all-cause mortality in quartiles 2,3 and 4 compared with quartile 1 (PAB <34.95). Using uni & multivariate conditional logistic regression with multiple adjustments, the PAB value remained significantly different for all-cause mortality. The result of the cause-specific mortality analysis showed that the mean PAB was highest in COVID-19 infection and the respiratory diseases, and lowest in death caused by cardiovascular diseases (p < 0.05).

Conclusions: Increasing PAB levels were significantly associated with increasing all-cause mortality suggesting that PAB measurement may have utility in indicating disease severity and have differential prognostic value in acute and chronic clinical scenarios.

查看原文本刊更多论文

促氧化-抗氧化平衡作为死亡率的预测因子：来自Neyshabur衰老纵向研究的发现。

背景：本研究的目的是确定PAB水平作为成人和老年受试者全因和病因特异性死亡率的预测因子。方法：研究期间死亡的386名受试者的数据与存活的386名受试者的年龄和性别相匹配，并比较PAB水平。采用混合酶/化学方法对PAB进行评价，其中促氧化剂和抗氧化剂分别同时氧化和还原显色剂3,3',5,5'-四甲基联苯胺，导致可测量的比色变化。结果：PAB水平显示死亡风险增加(OR: 1.018；95%CI: 1.010-1.025, p . p .结论：PAB水平升高与全因死亡率升高显著相关，表明PAB测量可能在指示疾病严重程度方面具有实用价值，并在急性和慢性临床情况下具有不同的预后价值。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Biomarkers in medicine 医学-医学：研究与实验

CiteScore

3.80

自引率

4.50%

发文量

审稿时长

6-12 weeks

期刊介绍： Biomarkers are physical, functional or biochemical indicators of physiological or disease processes. These key indicators can provide vital information in determining disease prognosis, in predicting of response to therapies, adverse events and drug interactions, and in establishing baseline risk. The explosion of interest in biomarker research is driving the development of new predictive, diagnostic and prognostic products in modern medical practice, and biomarkers are also playing an increasingly important role in the discovery and development of new drugs. For the full utility of biomarkers to be realized, we require greater understanding of disease mechanisms, and the interplay between disease mechanisms, therapeutic interventions and the proposed biomarkers. However, in attempting to evaluate the pros and cons of biomarkers systematically, we are moving into new, challenging territory. Biomarkers in Medicine (ISSN 1752-0363) is a peer-reviewed, rapid publication journal delivering commentary and analysis on the advances in our understanding of biomarkers and their potential and actual applications in medicine. The journal facilitates translation of our research knowledge into the clinic to increase the effectiveness of medical practice. As the scientific rationale and regulatory acceptance for biomarkers in medicine and in drug development become more fully established, Biomarkers in Medicine provides the platform for all players in this increasingly vital area to communicate and debate all issues relating to the potential utility and applications. Each issue includes a diversity of content to provide rounded coverage for the research professional. Articles include Guest Editorials, Interviews, Reviews, Research Articles, Perspectives, Priority Paper Evaluations, Special Reports, Case Reports, Conference Reports and Company Profiles. Review coverage is divided into themed sections according to area of therapeutic utility with some issues including themed sections on an area of topical interest. Biomarkers in Medicine provides a platform for commentary and debate for all professionals with an interest in the identification of biomarkers, elucidation of their role and formalization and approval of their application in modern medicine. The audience for Biomarkers in Medicine includes academic and industrial researchers, clinicians, pathologists, clinical chemists and regulatory professionals.